Catalent Pharma Solutions has successfully completed its collaboration with BioAlliance Pharma on the development, approval and launch of Miconazole 50mg buccal tablets for the treatment of oropharyngeal candidiasis. The product has been marketed in several European countries since 2007 under the name Loramyc, and was approved by the FDA in April. The product has launched in the U.S. under the trade name Oravig, by Strativa Pharmaceuticals Inc., a division of Par Pharmaceuticals. Catalent provid...